CyberKnife radiosurgery for inoperable stage IA non-small cell lung cancer: 18F-fluorodeoxyglucose positron emission tomography/computed tomography serial tumor response assessment
Open Access
- 4 February 2010
- journal article
- clinical trial
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 3 (1) , 6
- https://doi.org/10.1186/1756-8722-3-6
Abstract
To report serial 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT) tumor response following CyberKnife radiosurgery for stage IA non-small cell lung cancer (NSCLC). Patients with biopsy-proven inoperable stage IA NSCLC were enrolled into this IRB-approved study. Targeting was based on 3-5 gold fiducial markers implanted in or near tumors. Gross tumor volumes (GTVs) were contoured using lung windows; margins were expanded by 5 mm to establish the planning treatment volumes (PTVs). Doses ranged from 42-60 Gy in 3 equal fractions. 18F-FDG PET/CT was performed prior to and at 3-6-month, 9-15 months and 18-24 months following treatment. The tumor maximum standardized uptake value (SUVmax) was recorded for each time point. Twenty patients with an average maximum tumor diameter of 2.2 cm were treated over a 3-year period. A mean dose of 51 Gy was delivered to the PTV in 3 to 11 days (mean, 7 days). The 30-Gy isodose contour extended an average of 2 cm from the GTV. At a median follow-up of 43 months, the 2-year Kaplan-Meier overall survival estimate was 90% and the local control estimate was 95%. Mean tumor SUVmax before treatment was 6.2 (range, 2.0 to 10.7). During early follow-up the mean tumor SUVmax remained at 2.3 (range, 1.0 to 5.7), despite transient elevations in individual tumor SUVmax levels attributed to peritumoral radiation-induced pneumonitis visible on CT imaging. At 18-24 months the mean tumor SUVmax for controlled tumors was 2.0, with a narrow range of values (range, 1.5 to 2.8). A single local failure was confirmed at 24 months in a patient with an elevated tumor SUVmax of 8.4. Local control and survival following CyberKnife radiosurgery for stage IA NSCLC is exceptional. Early transient increases in tumor SUVmax are likely related to radiation-induced pneumonitis. Tumor SUVmaxvalues return to background levels at 18-24 months, enhancing 18F-FDG PET/CT detection of local failure. The value of 18F-FDG PET/CT imaging for surveillance following lung SBRT deserves further study.Keywords
This publication has 26 references indexed in Scilit:
- A Pilot Trial of Serial 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients With Medically Inoperable Stage I Non–Small-Cell Lung Cancer Treated With Hypofractionated Stereotactic Body RadiotherapyInternational Journal of Radiation Oncology*Biology*Physics, 2009
- Treatment of malignant tumors of the skull base with multi-session radiosurgeryJournal of Hematology & Oncology, 2009
- Radiation produces differential changes in cytokine profiles in radiation lung fibrosis sensitive and resistant miceJournal of Hematology & Oncology, 2009
- Recent advances of novel targeted therapy in non-small cell lung cancerJournal of Hematology & Oncology, 2009
- Radical cyberknife radiosurgery with tumor tracking: an effective treatment for inoperable small peripheral stage I non-small cell lung cancerJournal of Hematology & Oncology, 2009
- A Comparison of the Diagnostic Accuracy of18F-FDG PET and CT in the Characterization of Solitary Pulmonary NodulesJournal of Nuclear Medicine, 2008
- Radical stereotactic radiosurgery with real-time tumor motion tracking in the treatment of small peripheral lung tumorsRadiation Oncology, 2007
- Dose distributions in SBRT of lung tumors: Comparison between two different treatment planning algorithms and Monte-Carlo simulation including breathing motionsActa Oncologica, 2006
- Stereotactic hypofractionated high‐dose irradiation for stage I nonsmall cell lung carcinomaCancer, 2004
- Wedge Resection Margin Distances and Residual Adenocarcinoma in Lobectomy SpecimensAmerican Journal of Clinical Pathology, 2003